Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

AstraZeneca Gets a Boost from U.S. Travel Rules Tweak, Breast Cancer Drug Trial

Published 21/09/2021, 11:00 pm
Updated 21/09/2021, 11:00 pm
© Reuters.

© Reuters.

By Dhirendra Tripathi

Investing.com – AstraZeneca ADRs (NASDAQ:AZN) traded 1% higher in Tuesday’s premarket as the proposed changes to rules governing travel to the U.S. will accommodate those vaccinated by the company’s Covid-19 shots.

The Oxford-AstraZeneca vaccine is still not approved by the U.S. drugs regulator. But according to comments made by Anthony Fauci, a top infectious diseases expert who heads the U.S. response to the pandemic, it looks like those vaccinated by the vaccine will face no problem entering the U.S.  

“Given we have a substantial amount of information on the AZ vaccine . . . I would predict it would not be a problem,” he said, according to The Times of London.

The U.S. eased travel rules Monday, allowing fully vaccinated travelers to enter the country from November onward without them having to quarantine. They will have to present a proof of vaccination before boarding and proof of a negative Covid-19 test taken within three days of the flight.

The easing of travel rules and Fauci’s comments added to the positive sentiment for the stock generated by the findings of a study involving the company’s potential drug to treat breast cancer. The company on Saturday said Enhertu, an antibody drug conjugate, demonstrated superior outcomes compared to the existing treatment. The company is jointly developing the drug with Japan’s Daiichi Sankyo (T:4568).

 

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.